Gene Therapy: A'One and Done' Hemophilia B Treatment? Gene Therapy: A'One and Done' Hemophilia B Treatment?
Nearly all patients treated with a one-time gene therapy shot for hemophilia B were able to discontinue full-dose bleeding prophylaxis, says a study. Annual bleed rates fell by 64% after the lead-in period.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 22, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Post –COVID Vaccine AHA Cases Raise Eyebrows in Italy Post –COVID Vaccine AHA Cases Raise Eyebrows in Italy
"The overall number of cases observed does not allow...any definitive conclusion over a possible causal relationship between SARS-CoV-2 vaccination and AHA [acquired hemophilia A]."Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
New Approaches to Hemophilia Treatment:'Our Cup Runneth Over'New Approaches to Hemophilia Treatment:'Our Cup Runneth Over '
New approaches to treating hemophilia may soon replace the decades-old approach of using factor concentrates to control bleeding in patients with hemophilia A and hemophilia B.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Fitusiran: Great'Leap Forward' in Hemophilia Treatment Fitusiran: Great'Leap Forward' in Hemophilia Treatment
Instead of taking the traditional approach of replacing what ' s missing, the idea of fitusiran is to short circuit the body ' s anticoagulation system by targeting antithrombin.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche ’s Hemlibra in people with moderate or mild haemophilia A
Basel, 13 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from an interim analysis of the phase III HAVEN 6 study, which show Hemlibra ® (emicizumab) demonstrated a favourable safety profile and effective bleed control in people with moderate or mild haemophilia A without factor VIII inhibitors.3 The data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition as an oral presentation on 12 December 2021. (Source: Roche Media News)
Source: Roche Media News - December 13, 2021 Category: Pharmaceuticals Source Type: news
Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche ’s Hemlibra in people with moderate or mild haemophilia A
Basel, 13 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from an interim analysis of the phase III HAVEN 6 study, which show Hemlibra ® (emicizumab) demonstrated a favourable safety profile and effective bleed control in people with moderate or mild haemophilia A without factor VIII inhibitors.3 The data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition as an oral presentation on 12 December 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - December 13, 2021 Category: Pharmaceuticals Source Type: news
Blood plasma isn’t effective therapy for covid, but it’s vital for other illnesses
Plasma from healthy individuals is used to treat hemophilia and forms of liver and kidney disease. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - December 12, 2021 Category: Consumer Health News Authors: Zoe Zorka Source Type: news
Gene Therapy Could Be Big Advance Against Hemophilia
Title: Gene Therapy Could Be Big Advance Against HemophiliaCategory: Health NewsCreated: 11/18/2021 12:00:00 AMLast Editorial Review: 11/18/2021 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - November 18, 2021 Category: Anesthesiology Source Type: news
Past the tipping point: a qualitative study of the views and experiences of men with haemophilia regarding mobility, balance, and falls - Taylor S, Toye F, Donovan-Hall M, Barker K.
PURPOSE: The life expectancy of people with haemophilia is increasing due to improved medical care. This improvement is accompanied by the co-morbidities of ageing, which include musculoskeletal degeneration and the associated effect on proprioception and ... (Source: SafetyLit)
Source: SafetyLit - October 18, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Prophylactic factor IX therapy cost effective for children with haemophilia B in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news
New data for Roche ’s Hemlibra reinforce safety profile in people with haemophilia A
Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra ® (emicizumab), consistent with the phase III HAVEN clinical programme.1,2,3,4 In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with haemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congre...
Source: Roche Media News - July 19, 2021 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Hemlibra reinforce safety profile in people with haemophilia A
Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra ® (emicizumab), consistent with the phase III HAVEN clinical programme.1,2,3,4 In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with haemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congre...
Source: Roche Investor Update - July 19, 2021 Category: Pharmaceuticals Source Type: news
Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
Basel, 02 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, from 17-21 July 2021. Data will include the final analysis from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group).1,2 (Source: Roche Media News)
Source: Roche Media News - July 2, 2021 Category: Pharmaceuticals Source Type: news
